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Neither the pathogenesis of psoriasis nor the mecha-
nism whereby seemingly diverse therapies alter the dis-
ease is understood. In this study, several antipsoriatic 
agents were tested for their effects on the skin cell 
lymphocyte reaction (SLR), an immunologic assay in 
which HLA-DR antigens on Langerhans cells (LC) stim-
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Abbreviations: 
Con-A: concanavalin A 
EB: ethidium bromide 
ulate proliferation of allogeneic lymphocytes . Every 
agent tested (cortisol, methotrexate, hyperthermia, an-
thralin) inhibited the SLR at therapeutic dose levels. By 
contrast, a variety of antibiotics, an anti-inflammatory 
agent, and lithium carbonate and propranolol, two drugs 
known to be ineffective in psoriasis, failed to inhibit the 
FCS: fe tal calf serum 
FDA: fluorescein diacetate 
CHJdThd: trit iated thymidine 
HLA-DR antigen: the human equiyalent of the murine Ia or 
immune response-associated antigen 
LC: Langerhans cells 
8-MOP: 8-methoxypsoralen 
MTX: methotrexate . 
PBML: peripheral blood mononuclear leukocytes 
PBS: phosphate-buffered saline 
PUV A: photoactivated 8-methoxypsoralen 
SLR: skin cell lymphocyte reaction 
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SLR. Finally, we have shown that hyperthermia and 
anthralin treatments are toxic for LC whereas they have 
little or no effect on k eratinocyte viability. These results 
su ggest that antipsoriatic a gents may act in psor iasis by 
alte ration or killing of LC. 
Psoriasis is a disease of unknown etiology ch aracterized by 
hyperproliferat ion of keratinocytes (1]. Photochemotherapy 
with 8-methoxypsoralen (8-MOP ) and long-wavelength ultr a-
violet r adiation (360 nm) , termed P UV A, usually resul ts in 
clearing of psoriasis [2]. In this regard, it is interesting that 
P UV A is effective in a number of skin diseases thought to have 
a n immunologic basis (e.g., vitiligo, alopecia ar ea ta ) (3,4]. We 
recently reported t hat the in vitro t rea tm ent of skin cells with 
P UV A inhibits t he capacity of these cells to stimula te allogeneic 
lymphocytes in t he skin cell lymphocyte reaction (SLR) [5]. In 
th e current study, we tested other ant ipsoriatic treatments for 
their effects on the SLR, which represents the proliferative 
response of T-lymphocytes to HLA-DR antigen expressed on 
epidermal Langer h ans cells (LC) [6, 7). The results indicate th a t 
every antipsoriat ic agen t tested is a poten t inhibitor of th e SLR 
whereas a varie ty of antibiotics, an ti-inflammatory agents, and 
other dr ugs known to be ineffective in psoriasis have no inhib-
itory effect. The possibility that inhibition of this immune 
response is related to therapeutic efficacy in psoriasis is dis-
cussed. 
MATERIALS AND METHODS 
Preparation of S llin Cells 
Single cell suspensions of skin cells, consisting m ainly of epidermal 
cells, were prepared from normal skin obtained at surgery according to 
the method of Liu and Karasek (8]. Briefly, tl'im med skin was cut in to 
1 X 5 em strips and split -cut with a Castroviejo kera totome set at 0.1 
mm prior to treatment for 30 min at 37°C wi th 0.3% trypsin (Microbi-
ologica l Assoc. , Walkersville, M aryland) in 0.8% NaCl, 0.04% K Cl, 0.1% 
glucose, .084% N aH COa, at pH 7.3, plus 0.1% EDTA. The r esul tant 
dispersed cells were t hen suspended in complete RPMl medium (RPMI 
1640, Microbiological Assoc.) supplemented wi th 10% decomplemented 
pooled human serum, 2 mM L-glu tamine, 100 units/ml penicillin, 50 j.!g/ 
ml gentamicin, and 100 j.!g/ml strep tomycin) at a concen tration of 5 x 
10'' cells/mi. 
"Panning'' 
A 10 x 2.5 em Lab Tek Petri dish (Scien tific Products) was coated 
with goat an timouse IgG (Tago, Inc.) at 10 j.!g/ml in 0.05 M T ris buffer, 
pH 9.5 [9]. The plates were washed 3 times with phosphate-buffered 
saline (PBS ) and once with 5% fetal calf serum (FCS) in PBS. Dispersed 
epidermal cells (30 X 10H) were incubated with 1 ml OKT6 (dilu ted 1:50 
in PBS ) for 20 min at room temperatUTe. The cells were wash ed twice 
with PBS, resuspended in 5% FCS/PBS (5 x 106 cells/ml), and 3 ml of 
this cell suspension was laye red onto 1 Petri dish surface, incubated at 
4 °C for 40 min, swirled , and incubated for another 30 min [9}. The 
supernatant containing unattached cells was poured off gently, t he 
Petri dish surface washed 5 t imes wi th 1% FCS/PBS, and the attached 
cells were scraped off with a rubber policeman. 
Shin Cell-Lymphocyte R eaction (S LR) 
Viable epidermal cells (5 X 10'1) or LC-enriched or LC-depleted 
epidermal cell fractions were coincubated wi th 5 X 10" a llogene ic 
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periphera l blood m ononuclear leukocytes (PBML) in complete RPMI 
medium in microtiter wells at 37°C in an atmosphere of 5% C0 2/95% 
air [10}. On the sixth day of culture, 1 j.!Ci of ["H] thymidine (["H]dThd) 
(New England Nuclear , Boston, M assachusetts) was added per well, 
and 18 h later the cul tures were harvested with a Mash II appa ratus 
(Microbiological Assoc., Bethesda, M aryland) . The incorporation of 
["H}dThd was measured in a liquid scintillation coun ter (B eckman , 
Irvine, California ). 
S timulation of PBML with Concanavalin A 
One hundred th ousand PBML were incubated in 0.2 ml of complete 
R PMI in microtiter wells. At the time of incubation, a ll of the cells 
received 50 llg/ml concanavalin A (Con-A) to stimulate D N A synthesis . 
At t he same time, some cells were treated additiona lly with various 
concen trations of cor tisol. Three days later, ["H]dThd (lMCi!well) was 
added and 18 h later the cells were har vested with a Mash II apparatus. 
A ssessment of Cell Viability 
At various t ime in terva ls, the viabili ty of skin cells was assessed 
either by trypan blue exclusion or with a sensitive flu orochromatic 
assay [11]. Briefly, 1.0 ml of cell suspension was incubated wi th 0.1 ml 
o£0.01% fluor escein diacetate (FDA) for 5 min in the dark, washed wi th 
PBS, and resuspended at 2 X 10" ceLls/ml in complete kera tinocyte 
growth m edium. One drop of this suspension was placed on a slide with 
5 j.!l of ethidium bromide (EB) (0.04% in PBS ) and examined immedi-
a tely with a flu orescence microscope. Live ce lls show green flu orescence 
whereas dead cells stain red. 
Anthmlin Treatment 
One milligram of anthralin powder (K &K Labs, P la inview, New 
York) was dissolved in 1 ml acetone, and 9 ml of complete growth 
medium was added to achieve a stock concentration of 100 1-Lg/ml. P rior 
to use, this solution was exposed to air for at least 20 min to allow 
evaporation of the acetone. Cells were incubated at 37°C for 2 h wi th 
anthralin at concentrations up to 10 j.lg/ml, washed once wi th 5 ml of 
complete growth medium, and resuspended in complete RPMI prior to 
addition to the SLH. Viability was determined at 24 and 48 h. S ince 
an thra lin treatment r esults in brown discolora tion of cells which might 
cause quenching in the scin tillation counter, a quench curve was 
obtained . At t he ant hra lin concentrations used, no quenching resul ted. 
Hyp erthermia Treatment 
One million dispersed skin cells in complete growth medium were 
aliquoted into 6-cm Petri dishes (Lux, M . A. Bioproducts, Walkersville, 
Maryland) and placed in a water bath con trolled to ± 1 oc and heated 
to 43°C fo r up to 4.5 h. After treatment, th e cells were removed from 
the plates and resuspended in complete R P MI prior to addition to the 
SLR. Viability was determined at 1, 24, and 48 h. 
Hydrocortisone, Epicortisol, and M ethotrexate (MTX) Treatment 
Dispersed cells were incubated wi th vaJ·ious concen tra tions of hydJ·o-
cortisone and epicortiso\, ranging from 10- '• M to 10- 8 M, for 24 h in 
complete growth medium. In a separate experimen t, skin cells were 
incubated in up to 50 j.!g/ml MTX. The cells were washed twice in 
complete growth medium and resuspended in complete RPMI m edium 
prior to addition to the SLR. Viability was determined at 24 and 48 h. 
In another series' of experimen ts, cor tisol and MTX were m aintained in 
the culture medium for the dul'ation of the SLR. 
Treatment with Other Agents 
A variety of "control" agen ts not known to be efficaci_ous in psoriasis 
were tested for their effects on t he SLR by adding various concen tra-
T A BLE I. Effect of pretreatment of skin cells with anthmlin on the SLR 
An thralin 
pretreatment (2 h) 
None" 
0.1 /lg/ml 
0.5 j.!g/m1 
2.5 j.!g/ml 
10.0 j.!g/ml 
D onor A 
43,991 ± 4,020 " 
30,273 ± 3,512 
34,860 ± 3,641 
12,648 ± 1,105 
101 ± 15 
Response of allogeneic lym phocytes (cpm)" 
Donor B 
31,327 ± 3,033 
40,663 ± 4,038 
43,765 ± 4,417 
2,688 ± 2,556 
298 ± 25 
Donor C 
41 ,047 ± 4,024 
35,529 ± 3,450 
33,792 ± 3,214 
508 ± 63 
798 ± 71 
" R esponder lymphocytes incuba ted a lone incorporated less than 1000 cpm. 
Do nor D 
26,400 ± 2,858 
39,891 ± 4,289 
24 ,856 ± 2,582 
17,167 ± 1,760 
103 ± 19 
1
' Control cells were treated with th e same concentration of acetone (1 %) as t hose cells which received t he highest a nthralin concent ration. 
,. Mean of triplicate wells ± SEM. 
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tions of drugs to skin cell suspensions 2 h before addition of allogeneic 
lymphocytes and mainta ining the cells in the drug for t he duration of 
the SLR. D rugs tested included gentamicin, penicillin, streptomycin, 
indomethacin, li thium carbonate (Li"CO"), a nd propra nolol. 
RESULTS 
Effect of Anthralin on the SLR 
Pretreatment of skin cells with anthralin resulted in dose-
dependent inhibition of the SLR. As shown in Table I, prein-
cubation with 0.5 llg/ml or less anthralin failed to inhibit the 
SLR, whereas 10 flg/ml completely blocked the reaction. To 
rule out the possibility that the inhibition of the SLR was due 
to an effect on responder cells of anthralin eluted from stimu-
lator cells during the 7-day incubation, we added 2.5 X 104 
anthralin-pretreated (10 flg / ml for 2 h ) epidermal cells to 2.5 
x 10'1 untreated epidermal cells and incubated them with 5.0 
x 10• allogeneic responder lymphocytes (Table II). The capac-
ity of untreated skin cells coincubated with anthralin-pretreated 
skin cells to stimulate allogeneic lymphocytes was the same as 
untreated skin cells coincubated without a nthralin-pretreated 
cells. Thus, anthralin is not leached out of stimulator cells 
during the 7-day coincubation with allogeneic lymphocytes; the 
TABLE II. Effect of anthralin-pretreated shin cells on the capacity 
of untreated skin cells to stimulate allogeneic PBML 
Pretreatment (I 
( 10 l'g/ ml anthralin) 
for 2 h) 
None (2.5 x 10'' cells ) 
Anthralin (2.5 x 10'' cells) plus 
untreated cells (2.5 X 10'1) 
Response of allogeneic lymphocytes 
(cpm) 1' 
Donor A 
45,813 ± 3,779c 
52,056 ± 4,473 
Donor B 
22,488 ± 931 
22,339 ± 2,651 
" In this experiment anthra lin pretreatment (10 ,ug/ ml for 2 h) of 
stimulator cells resulted in over 50% inhibi tion of the SLR. 
"Responder lymphocytes incubated a lone incorporated less t han 
1000 cpm. 
<Mean of triplicate wells ± SEM. 
TABLE III. Effect of pretreatment of shin cells with hyperthermia on 
the SLR 
Inhibition of response of allogeneic lymphocytes (% control) 
Heat (43°C) 
pretreatment Exp 1 Exp ll Exp Ill Exp IV (h) 
Donor 6 Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 
1 43.2 53.8" 27.7" 54.9" 
1.5 27.9" 54 .8 35.5" 
2 1.6" 25.9" 3.3" 
2.5 4.1" 27.4" 3.0" 
3 1.0" 2.1" 2.0" 
4.5 1.9 " 0.4" 4.0" 
"Statistica lly significant inhibition (p < .05). 
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inhibition seen in the SLR by antlu·alin pretreatment of skin 
cells must be due to an effect on the stimulator cells alone. 
Effect of Hyperthermia on the SLR 
As shown in Table III, preincubation of skin cells at 43°C for 
2 h or longer significantly inhibited the capacity of these cells 
to stimulate in the SLR. Similar results were obtained in 4 
separate experiments using PBML from 6 unrelated individuals 
as responde~ cells. 
Effect of Cortisol on In Vitro Immune Responses 
Skin cells were preincubated with concentrations of cortisol 
ranging from 10- 8 M to 10- 5 M for 24 h before coincubation with 
allogeneic lymphocytes in the SLR. None of the concentrations 
tested resulted in inhibition of the capacity of skin cells to 
stimulate in the SLR (not shown). On the other hand, addition 
of the same concentrations of cortisol to the incubation medium 
at the time of coincubation of skin cells and PBML and main-
tenance in the medium for 7 days resulted in dose-dependent 
inhibition of the SLR (Table IV). As a control for these exper-
iments, we used epicortisol, an isomer of cortisol known as an 
inactive steroid [12]. As high as 10- 5 M epicortisol in the 7-day 
incubation medium did not result in inhibition of the SLR 
(Table IV). 
To determine whether the effect of cortisol is only on the 
stimulator cell population or whether all or part of the effect is 
on the responder cell population, PBML were incubated with 
Con-A plus varying concentrations of cortisol (Table V). Cor-
tisol concentrations above 10- 7 M decreased the Con A-induced 
stimulation of PBML although the effect after the 4 days of 
incubation used for this assay is not as strong as that seen after 
7 days of incubation in t he SLR (Table IV). 
Effect of MTX on the SLR 
Preincubation of skin cells for 24 h with MTX at concentra-
tions as high as 50 flg/ ml did not affect the capacity of these 
cells to stimulate allogeneic lymphocytes (not shown). By con-
trast, addition of as little as 0.2 flg / ml to the incubation medium 
TABLE V. Effect of cortisol on Con-A stimulation of PBML 
Stimulus 
Con-A only" 
w-• M Cortisol + Con-A 
10- 7 M Cortisol + Con-A 
w-" M Cortisol + Con-A 
w-" M Cortisol + Con-A 
Response of PBML (cpm) 
Donor A 
60,827 ± 8,968 " 
60,737 ± 1,253 
48,510 ± 5,440 
24,636 ± 3,190 
22,973 ± 152 
Donor B 
77,426 ± 7,257 
79,493 ± 11,107 
87,799 ± 2,678 
36,625 ± 499 
38,553 ± 3,163 
" All cultures were incubated with 50 ,ug/ ml Con-A. All drugs were 
added only once-at the time of lectin addition to PBML. 
" Mean of triplicate wells ± SEM. 
TABLE IV. Effect of cortisol or epicortisol on the SLR 
Response of allogeneic lymphocytes (cpm) 
Treatment" 
Donor B Donor C Donor D Donor A 
None" 48,651 ± 3,634 c 22,707 ± 3,105 56,355 ± 8,515 22, 160 ± 2,839 
w-a M Cortisol 34,379 ± 2,871 22,871 ± 994 42,507 ± 5,286 22,591 ± 1,556 
10- 7 M Cortisol 20,346 ± 2,327 15,471 ± 4,964 24,496 ± 4,673 15,900 ± 6, 782 
w-" M Cortisol 12,389 ± 1,162 7,053 ± 1,024 20,337 ± 3,402 13,339 ± 7,132 
w-• M Cortisol 7,359 ± 1,027 8,126 ± 834 10,984 ± 1,610 7,245 ± 1,626 
w-s M Epicortiso l 78,376 ± 7,297 34,873 ± 9,821 NT" NT 
10- 7 M Epicortisol 64,420 ± 7,257 22,730 ± 3,097 NT NT 
10- 6 M Epicortisol 52,371 ± 6,503 31,039 ± 2,951 NT NT 
w-" M Epicortisol 52,773 + 8,543 41,941 + 4,385 NT NT 
" The steroid was added only once-at the time of coincubation with allogeneic lymp~ocytes. _
0 
· • • • . 
" These cells were incubated with the same amoun t of ethanol (0.1 %) as was present m the 10 cortisol a nd eptcortisol medta. 
c Mean of triplicate wells ± SEM. 
" NT = not tested. 
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at the time of coincubation of skin cells and PBML and main-
tenance in the medium for 7 days completely inhibited the 
capacity of lymphocytes to respond to allogeneic skin cells 
(Table VI) . 
Effect of Other Agents on the SLR 
To determine whether the observed inhibi tion of the SLR 
was specific to drugs useful in the treatment of psoriasis, we 
studied the effect on the SLR of 2 drugs (propranolol and 
Li2COa) not used for psoriasis therapy, but reported to exacer-
bate the disease in some instances [13,14]. Propranolol was 
tested at concentrations ranging from 10- '' M to 10- 6 M and 
Li2C0 3 was tested at concentrations ranging from 0.30 mg/ rnl 
to 0.03 mg/ rnl. These levels are in the therapeutic range reached 
in the serum in vivo [15,16]. Both of these drugs were added to 
the epidermal cell suspension 2 h before coincubation with 
allogeneic lymphocytes and maintained in the cuJtme medium 
for 7 days of incubation to insw·e maximum exposure of cells to 
the drugs. At th ese concentrations, neither drug inhibited the 
TABLE VI. Effect of MTX on the SLR 
Concentration 
of MTX (l'g/ ml)" 
Response in SLR (cpm)'' 
None 
0.2 
1.0 
5.0 
50.0 
Donor A 
29,923 ± 4,036 ' 
2,894 ± 474 
2,033 ± 21 
1,360 ± 139 
1,750 ± 305 
Donor B 
43,831 ± 5,652 
4,398 ± 219 
3,434 ± 521 
3,495 ± 79 
3,697 ± 674 
" MTX was added to the incubation medium at the time culture was 
ini tiated between skin cells and a llogeneic lymphocytes. 
" T he incorpora tion of 3H-T in to responde1· lymphocytes when in-
cubated a lone was 1,397 cpm (Donor A) and 2,528·cpm (Donor B). 
·· Mean of triplicate wells ± SEM. 
TABLE VII. Viability of u.nfraction.a.ted shin cells after exposure to 
various agents 
Viabili ty (%viable)" 
'TreaLment 
Day O'' Day I Day 2 
None 86'" 77 56 
Acetone (only) 73 82 66 
0.1 IJ.g/ ml Anthra lin " 91 NT'" 60 
0.5 llg/ ml Anthralin 86 NT 58 
2.0 !lg! ml Anth ra l.in 86 80 55 
10.0 iJ.g/ ml Anthralin 83 81 67 
43°C fo r 1 h 83 79 65 
43 °C for 2 h 84 88 70 
43°C for 3 h 83 73 67 
43 °C for 4.5 h 78 87 63 
"Viabili t ies determined with FDA/ EB. 
" The viab ili ty of cells was determined immediately after treatment 
(day 0) and at 24 h (day I) and 48 h (day 2) a fter trea tment. 
,. Mean of dupl icate counts; variation is< 15%. 
''Cells were pretreated with the indicated anthralin concentrations 
for 2 h. 
• N .T = not tested. 
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SLR. Moreover, the addition of Li2C0:1 augmented the SLR of 
1 individual (not shown). 
A variety of other agents were tested for their effects on the 
SLR by addition to the culture medium but none had any effect 
(not shown). These d1·ugs included antibiotics (penicillin 100 
units/ ml, streptomycin 100 pg/ ml , and gentamicin 50 pg/ mJ) 
and the anti-inflammatory agent indomethacin (1 J.Lg/ ml and 10 
p.g/ml). 
The Effect of Anthralin and Hyperthermia on the Viability of 
Dispersed Epidermal Cells 
To assess the possibility that the inhibition of the SLR was 
due to a direct lethal effect of anthralin on skin cells, t he 
viability of anthralin-treated cells was compared to that of cells 
incubated with medium/acetone alone (Table VII). Over a 48-
h time period no s ignificant difference in viability between 
anthralin-pretreated and control cells at all concentrations 
tested (up to 10 pg/ ml anthralin) was seen (Table VII). To 
determine whether the viability of total skin cells was affected 
by hyperthermia over a 48-h period after treatment, the viabil-
ity of hyperthermia-treated cells also was determined using 
FDA/ EB (Table VII). Over 48 h, the viability of total skin cells 
treated for up to 4.5 h at 43°C did not differ significantly from 
untreated skin cells. 
The Effect of Hyperthermia and Anthralin on the Viability of 
LC 
To determine whether the inhibition of the SLR by treat-
ments useful in psoriasis was due to a selective effect of the 
treatment on the LC subpopulation, we enriched th e skin cell 
suspension for OKT6-posit ive (0KT6+) cells with a panning 
method (9]. We and others have shown recently that using this 
method 70% or more of attached cells are LC (17,18]. As shown 
in Table VIII, t he OKT6+ cells stimulate vigorously wh ereas 
OKT6-negative (0KT6-) cells are capable of very li ttle or no 
stimulation in the SLR. Fmthermore, hyperthermia (4 h at 
43°C) treatment of OKT6+ cells totally inhibits the capacity of 
these cells to stimulate in the SLR. Finally, we examined the 
viability of all cell fractions after hyperthermia and anthralin 
treatment. In this, as in previous experiments, the viabili ty of 
unseparated cells and LC-depleted cells did not decrease sig-
nificantly after either treatment (Tables IX, X) . However , the 
viability of OKT6+ cell fraction was markedly dect·eased by 
both anthralin and hyperthermia treatments. The same pattern 
of selective cytotoxicity by hyperthermia on LC-enriched skin 
cells was seen in a second separate experiment. 
TABLE IX. Viabilities of different slo:n. cell fractions at 1 h after 
hyp erthermia. treatment 
Cell 
treatment 
Viable " cells in various skin cell fractions (%) 
U nsepara ted 
55" 
48 
LC.enriched 
79 
20 
LC.depleted 
35 
4 l 
" Viabili ty was determined by the method of FDA/ EB s taining. 
" For each determ ination a total of 400 cells were coun ted; SEM < 
10% for a ll values. 
TABLE Vlll. Effect of hyperthermic~ 011 the capacity of L C·en.riched and L C·depleted shin cells to stim.ula.t,e in the SLR 
Stimulawr cell pretreatment 
None 
43°C fo r 4 h 
Dono1· A 
71,752 ' 
1,682 
LC·emiched 
Response of allogeneic lymphocytes" lo various skin cell fract.ions'' (cpm) 
Donor B 
66,641 
1,544 
Donor A 
8,201 
4,907 
LC-depleted 
Donor B 
2,719 
681 
Donor A 
42,708 
11,212 
U nseparaled 
Donor B 
26,669 
1,141 
"PBML from Donor A incubated with x-irradiated (6,000 rad) PBML from Donor A incorporated 665 cpm (autologous MLR) and when 
incubated with x- iJTadiated PBML from Donor B incorporated 59,151 cpm. PBML from Donor B incubated wi th x- irradiated PBML from Donor 
B incorporated 173 cpm and when incubated with x-irradiated PBML from Donor A incorporated 48,676 cpm. 
1
' Ini tial viabili ty for unsepara ted cells was 92%, for LC-depleted cells was 64%, and for LC-enri ched cells was 70%. 
,. Mean of triplicate wells; the SEM is always less than 20%. 
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TABLE X. Viabilities of different shin cell fra ctions after anthralin 
treatment 
Viable" cells in various skin cell fractions (%) 
Cell Unseparated LC-enriched LC-depleted treatment 
24 h" 48 h 24 h 48 h 24 h 48 h 
No ne e 45 ± 4" 30 ± 4 51± 4 41 ± 1 43 ± 1 33 ± 4 
Anthralin'· 47 ± 3 37 ± 4 10 ± 3 4 ± 1 35 ± 6 32 ± 1 
" Viability was determined by the method of FDA/EB staining. 
• The viabilities were determined at 24 and 48 h after drug incubation. 
c These cells were treated with the same concentration of acetone 
(0.2%) as the anthralin-treated cells. 
" Mean of triplicate values ± SD. 
' These cells were incubated in 10 l'g/ml anthralin for 2 h at 37°C; 
washed twice, and incubated in complete RPM! medium at 37°C. 
DISCUSSION 
These results, combined with previous reports, indicate that 
several agents effective in the treatment of psoriasis-anthralin, 
heat [19], PUV A [2,5], short-wave UV radiation [20], MTX 
[21], and cortisol-are inhibitory of the SLR at in vitro concen-
trations comparable to therapeutic dose levels. By contrast, a 
variety of antibiotics, epicortisol, and the nonsteroidal anti-
inflammatory agent indomethacin as well as 2 agents (Li2COa 
and propranolol) thought to exacerbate the disease had no 
inhibitory effect on the SLR. 
We and others have shown that only a small minority of skin 
cells have the capacity to stimulate in the SLR-those that 
express HLA-D/DR antigen and which, by distribution and 
morphology, correspond to bone marrow-derived LC [6,18,22-
24]. Thus, it is the functional integrity of these cells that one 
assays in the SLR. In the series of experiments reported here, 
we have demonstrated that the antipsoriatic treatments hyper-
thermia and anthralin act directly on LC. On this basis, it seems 
likely that the inhibitory effect of both of these agents on the 
SLR is mediated at least in part by the death of LC. Indeed, a 
recent report demonstrates that the number of LC in human 
epidermis decreases as monitored by electron microscopy after 
PUVA therapy [25]. Furthermore, after PUV A treatment the 
number of cells expressing HLA-DR in the epidermis is mark-
edly reduced [26]. Accordingly, the principal effects of locally 
active antipsoriatic agents such as hyperthermia, short-wave 
UV radiation, and anthralin may be to interfere with immune 
cell interactions in the skin that lead secondarily to proliferation 
of keratinocytes. Such a mechanism has been suggested previ-
ously to explain the therapeutic effects of PUVA [5,27]. 
Two drugs, cortisol and MTX, inhibit the SLR only when 
present continuously during the culture with allogeneic PBML. 
Furthermore, cortisol inhibits the capacity of PBML to respond 
to lectin, suggesting that inhibition in the SLR by this drug 
may be due, at least in part, to an effect on responder cells. 
Regardless of the precise site of action of cortisol and MTX 
(responder cells or stimulator cells), the observation that each 
drug is inhibitory of the SLR clearly demonstrates that these 
drugs inhibit a cellular immune response. 
Experiments by us and others have documented that cortisol 
does not inhibit proliferation of human keratinocytes cultured 
in vitro. Indeed, cortisol (1.1 X 10- '; M) has been used to 
stimulate the growth of cultured human keratinocytes [28]. 
These observations appear paradoxical in view of the clearly 
established clinical efficacy of corticosteroids in the treatment 
of the hyperproliferation of keratinocytes that is characteristic 
of psoriasis. On the other hand, the concept that the hyperpro-
liferation of keratinocytes seen in the psoriatic plaque is due to 
an abnormal stimulation of keratinocyte growth by another cell 
type accommodates both the experimental and clinical obser-
vations. On this basis, we propose that immunocompetent cells 
play a major role in the pathogenesis of psoriasis and that 
antipsoriatic agents primarily affect immunocompetent cells 
and only secondarily lead to inhibition of keratinocyte growth. 
Hopefully, studies of the possible interactions between LC and 
ANTIPSORIATIC AGENTS INHIBIT THE SLR 27 
keratinocytes will clarify the role of the immune system m 
psoriasis. 
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